Evidence map›Paper›PMID 33299473›Full record

ArticleTherapeutic advances in medical oncology2020

Phase II randomized trial of a non-steroidal mouth wash for prevention and treatment of stomatitis in women with hormone receptor positive breast cancer treated with everolimus.

Parvin F Peddi, Merry Tetef, Paul Coluzzi, Karo K Arzoo, Eddie H Hu, Maurice J Berkowitz, David Chan, Dennis Moore, Brad Adams, Xiaoyan Wang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 75% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. A renaissance in targeting the PI3K/AKT/mTOR pathway.Nature reviews. Drug discovery · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Parvin F PeddiUniversity of California, Los Angeles, 2336 Santa Monica Blvd., Suite 304, Santa Monica, CA 90404, USA.ORCID https://orcid.org/0000-0002-8459-9828
Merry TetefUniversity of California, Los Angeles, CA, USA.
Paul ColuzziUniversity of California, Irvine, CA, USA.
Karo K ArzooUniversity of California, Los Angeles, CA, USA.
Eddie H HuUniversity of California, Los Angeles, CA, USA.
Maurice J BerkowitzUniversity of California, Los Angeles, CA, USA.
David ChanTorrance Health Association, Torrance, CA, USA.
Dennis MooreCancer Center of Kansas, Overland Park, KS, USA.
Brad AdamsUniversity of California, Los Angeles, CA, USA.
Xiaoyan WangUniversity of California, Los Angeles, CA, USA.
Sara A HurvitzUniversity of California, Los Angeles, CA, USA.
University of California, Los Angeles · USCancer Center of Kansas · USTorrance Memorial Medical Center · USUniversity of California, Irvine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStomatitis is a frequent dose limiting toxicity of everolimus, an approved therapy for patients with metastatic breast cancer. No randomized trials of a prophylactic measure to prevent mucositis have been reported.

methodsWe conducted a phase II, open-label trial in which patients with metastatic breast cancer starting everolimus were randomized to best supportive care (BSC)

resultsOf 61 evaluable patients, 32 were randomized to and treated with oral mucoadhesive and 29 with BSC. Any grade stomatitis developed in 46.9% (15/32) of study arm and 65.5% (19/29) of BSC arm patients (

conclusionHere we provide early evidence from the first randomized trial supporting the use of oral prophylactic mucoadhesive for everolimus-associated stomatitis. A trial comparing prophylactic oral mucoadhesive to steroid mouth wash may be warranted.

Indexed as

breast cancereverolimushormone receptor-positive breast cancermouth washmucositis

Identifiers

PMID33299473
PMCPMC7711222
OpenAlexW3107629485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.